Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4 Registration of securities issued in business combination transactions
- 4.2 First Supplemental Indenture - Penwest Pharmaceuticals Co.
- 4.3 Second Supplemental Indenture - Generics Bidco I, LLC
- 4.4 Third Supplemental Indenture - Ledgemont Royalty Sub LLC
- 4.5 Fourth Supplemental Indenture - Vintage Pharmaceuticals, LLC
- 4.6 Fifth Supplemental Indenture - American Medical Systems Holdings, Inc.
- 4.7 Sixth Supplemental Indenture - American Medical Systems, Inc.
- 4.8 Seventh Supplemental Indenture - Generics Bidco II, LLC
- 4.11 First Supplemental Indenture - American Medical Systems Holdings, Inc.
- 4.12 Second Supplemental Indenture - American Medical Systems, Inc.
- 4.13 Third Supplemental Indenture - Generics Bidco II, LLC
- 4.16 First Supplemental Indenture - American Medical Systems Holdings, Inc.
- 4.17 Second Supplemental Indenture - American Medical Systems, Inc.
- 4.18 Third Supplemental Indenture - Generics Bidco II, LLC
- 5 Opinion of Skadden, Arps, Slate, Meagher & Flom LLP
- 12 Statement Regarding Computation of Ratio of Earnings to Fixed Charges
- 21 Subsidiaries of the Registrant
- 23.1 Consent of Independent Registered Public Accounting Firm
- 23.2 Consent of Independent Registered Public Accounting Firm
- 23.3 Consent of Independent Registered Public Accounting Firm
- 25.1 Statement of Eligibility of Trustee, Indenture for 7.00% Senior Notes Due 2020
- 25.2 Statement of Eligibility of Trustee, Indenture for 7% Senior Notes Due 2019
- 25.3 Statement of Eligibility of Trustee, Indenture for 7 1/4% Senior Notes Due 2022
- 99.1 Form of Letter of Transmittal
- 99.2 Form of Letter to Clients
- 99.3 Form of Letter to Brokers
LSCP similar filings
Filing view
External links
Exhibit 12
RATIO OF EARNINGS TO FIXED CHARGES
Six Months Ended June 30 | Year Ended December 31 | Year Ended December 31 | ||||||||||||||||||||||
Actual | ||||||||||||||||||||||||
2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||||||||||||||||||
Earnings | ||||||||||||||||||||||||
Pretax Income | 202.073 | 420.698 | 359.660 | 391.828 | 353.250 | 233.734 | ||||||||||||||||||
Less Income from Equity Investees | — | (0.969 | ) | (0.893 | ) | (1.468 | ) | (0.598 | ) | 0.000 | ||||||||||||||
Plus Amortization of Capitalized Interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||||||||||||||||
Plus Distributed Income from Equity Investees | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||||||||||||||||
Plus Pre-tax loss from equity investees | 0.579 | 0.000 | 0.000 | 0.000 | 0.000 | 0.144 | ||||||||||||||||||
Plus Fixed Charges | 47.548 | 53.686 | 45.317 | 21.626 | 2.147 | 2.684 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Total Earnings | 250.200 | 473.415 | 404.084 | 411.986 | 354.799 | 236.562 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Fixed Charges | ||||||||||||||||||||||||
Interest Expense | 44.648 | 47.956 | 41.247 | 18.726 | 0.117 | 1.384 | ||||||||||||||||||
Interest Component of Rental Expense | 2.900 | 5.730 | 4.070 | 2.900 | 2.030 | 1.300 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Total Fixed Charges | 47.548 | 53.686 | 45.317 | 21.626 | 2.147 | 2.684 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Ratio of Earnings to Fixed Charges | 5.3 | 8.8 | 8.9 | 19.1 | 165.3 | 88.1 |